Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Investor	Date	% Owned	Market Value	Shares	Chg. Shares	Chg. Shares %	% Portfolio
Capital Research and Management Company	2025-09-30	18.81707%	$18.70B	47.7M	-392.2K	-0.8%	0.9%
The Vanguard Group, Inc.	2025-09-30	9.54476%	$9.48B	24.2M	243.1K	1.0%	0.1%
BlackRock, Inc.	2025-09-30	8.76924%	$8.71B	22.2M	383.6K	1.8%	0.1%
The Growth Fund of America	2025-09-30	4.92473%	$4.89B	12.5M	365.8K	3.0%	1.7%
State Street Global Advisors, Inc.	2025-09-30	4.57435%	$4.55B	11.6M	-169.2K	-1.4%	0.2%
Vanguard Index Funds - Vanguard Total Stock Market ETF
Vanguard Index Funds - Vanguard S&P 500 ETF
Geode Capital Management, LLC
The Investment Company of America
Invesco QQQ Trust, Series 1
JP Morgan Asset Management
Wellington Management Group LLP
AllianceBernstein L.P.
American Balanced Fund
New Perspective Fund
Loomis Sayles & Company, L.P.
AMCAP Fund
UBS Asset Management AG
Norges Bank Investment Management
Government Pension Fund Global

Vertex Pharmaceuticals Incorporated

Top Holders